Company news

Amneal Pharmaceuticals, Inc. news in 2026

Amneal Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Amneal Reports Third Quarter 2026 Financial Results

November 3, 2026

Amneal to Report Third Quarter 2026 Results on November 3, 2026

October 8, 2026

Amneal Announces FDA Approval and Launch of Lanreotide Injection

September 18, 2026

Amneal Completes Acquisition Of Kashiv

August 17, 2026

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

August 10, 2026

Amneal Reports Second Quarter 2026 Financial Results

July 29, 2026

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

July 17, 2026

Amneal to Report Second Quarter 2026 Results on July 30, 2026

July 9, 2026

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals

June 9, 2026

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

June 5, 2026

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

June 4, 2026

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

June 1, 2026

Amneal Agrees To Acquire Kashiv BioSciences For Total Payment Up To $1.1 Billion

May 11, 2026

Amneal Reports First Quarter 2026 Financial Results

May 7, 2026

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

April 22, 2026

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

April 22, 2026

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

April 20, 2026

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

April 13, 2026

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

April 8, 2026

Amneal to Report First Quarter 2026 Results on May 1, 2026

April 7, 2026

Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month

April 6, 2026

Amneal Pharmaceuticals: LLC Issues Voluntary Nationwide Recall of Magnesium Sulfate in Water for Injection, USP 4 g/100mL (NDC 70121-1720-3) due to a Product Mix-up with Tranexamic Acid in 0.7% Sodium Chloride Injection, 10 mg/mL

March 24, 2026

Amneal to Participate in Upcoming Investor Conference

March 5, 2026

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

January 28, 2026

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

January 27, 2026

Calls in 2026

Decks in 2026